Page 96 - e-CPG-SLE-8_5_24
P. 96

Management of Systemic Lupus Erythematosus

           ACKNOWLEDGEMENT

           The  CPG  DG  members  would  like  to  express  their  gratitude  and
           appreciation to the following for their contributions:
           •  Panel of external reviewers who reviewed the draft technically
           •  Technical Advisory Committee of CPG for their valuable input and
              feedback
           •  HTA and CPG Council for approval of the CPG
           •  Mr.  Latif  Abqari  Nazeri  and  Ms.  Rosazaddilah  Azaddin  for  the
              retrieval of evidence
           •  All those who have contributed directly or  indirectly to  the
              development of the CPG


           DISCLOSURE STATEMENT

           The panel members of both DG and RC had completed disclosure forms.
           None hold shares in pharmaceutical firms or act as consultants to such
           firms. Details are available upon request from the CPG Secretariat.


           SOURCE OF FUNDING

           The  development  of  the  CPG  on  Management  of  Systemic  Lupus
           Erythematosus was supported mainly by the MoH Malaysia and partly
           by the Malaysian Society of Rheumatology.





























                                      79
   91   92   93   94   95   96   97   98